However, new treatments such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (nsMRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) have been shown to effectively slow CKD progression5-7). Here, SLC5A2 is linked to chronic kidney disease.